ABSTRACT
We aimed to evaluate the role of the spinal lymphatic system in spinal cord injury and whether it has an impact on recovery after spinal cord injury. Flow cytometry was used to evaluate the changes in the number of microvesicles after spinal cord injury. Evans blue extravasation was used to evaluate the function of the lymphatic system. Evans blue extravasation and immunofluorescence were used to evaluate the permeability of blood spinal cord barrier. The spinal cord edema was evaluated by dry and wet weight.Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was used to evaluate apoptosis after spinal cord injury. Nuclear factor-kappa B pathway was detected by Western blot. Behavioral tests were used to evaluate limb function. Microvesicles released after spinal cord injury can enter the thoracic duct and then enter the blood through the lymph around the spine. After ligation of the thoracic duct, it can aggravate the neuropathological manifestations and limb function after spinal cord injury. The potential mechanism may involve nuclear factor-kappa B pathway.
Subject(s)
Recovery of Function , Spinal Cord Injuries , Spinal Cord , Spinal Cord Injuries/physiopathology , Spinal Cord Injuries/pathology , Spinal Cord Injuries/metabolism , Animals , Recovery of Function/physiology , Spinal Cord/metabolism , Spinal Cord/pathology , Spinal Cord/physiopathology , NF-kappa B/metabolism , Male , Apoptosis/physiology , Rats, Sprague-Dawley , Disease Models, Animal , Lymphatic System/physiopathology , Lymphatic System/pathology , Edema/pathology , Thoracic Duct/physiopathology , Female , Cell-Derived Microparticles/metabolismABSTRACT
Traumatic brain injury (TBI) can induce systemic coagulopathy and inflammation, thereby increasing the risk of mortality and disability. However, the mechanism causing systemic coagulopathy and inflammation following TBI remains unclear. In prior research, we discovered that brain-derived extracellular vesicles (BDEVs), originating from the injured brain, can activate the coagulation cascade and inflammatory cells. In this study, we primarily investigated how BDEVs affect systemic coagulopathy and inflammation in peripheral circulation. The results of cytokines and coagulation function indicated that BDEVs can lead to systemic coagulopathy and inflammation by influencing inflammatory factors and chemokines within 24 h. Furthermore, according to flow cytometry and blood cell counter results, we found that BDEVs induced changes in the blood count such as a reduced number of platelets and leukocytes and an increased percentage of neutrophils, macrophages, activated platelets, circulating platelet-EVs, and leukocyte-derived EVs. We also discovered that eliminating circulating BDEVs with lactadherin helped improve coagulopathy and inflammation, relieved blood cell dysfunction, and decreased the circulating platelet-EVs and leukocyte-derived EVs. Our research provides a novel viewpoint and potential mechanism of TBI-associated secondary damage.
Subject(s)
Blood Coagulation Disorders , Brain Injuries, Traumatic , Extracellular Vesicles , Humans , Brain Injuries, Traumatic/complications , Inflammation/complications , Brain , Blood Coagulation Disorders/etiologyABSTRACT
Traumatic brain injury (TBI) can negatively impact systemic organs, which can lead to more death and disability. However, the mechanism underlying the effect of TBI on systemic organs remains unclear. In previous work, we found that brain-derived extracellular vesicles (BDEVs) released from the injured brain can induce systemic coagulation with a widespread fibrin deposition in the microvasculature of the lungs, kidney, and heart in a mouse model of TBI. In this study, we investigated whether BDEVs can induce heart, lung, liver, and kidney injury in TBI mice. The results of pathological staining and related biomarkers indicated that BDEVs can induce histological damage and systematic dysfunction. In vivo imaging system demonstrated that BDEVs can gather in systemic organs. We also found that BDEVs could induce cell apoptosis in the lung, liver, heart, and kidney. Furthermore, we discovered that BDEVs could cause multi-organ endothelial cell damage. Finally, this secondary multi-organ damage could be relieved by removing circulating BDEVs. Our research provides a novel perspective and potential mechanism of TBI-associated multi-organ damage.
Subject(s)
Brain Injuries, Traumatic , Brain Injuries , Extracellular Vesicles , Mice , Animals , Brain/pathology , Brain Injuries/pathology , Apoptosis , Extracellular Vesicles/pathologyABSTRACT
BACKGROUND: Contact sports athletes and military personnel who suffered a repetitive mild traumatic brain injury (rmTBI) are at high risk of neurodegenerative diseases such as advanced dementia and chronic traumatic encephalopathy (CTE). However, due to the lack of specific biological indicators in clinical practice, the diagnosis and treatment of rmTBI are quite limited. METHODS: We used 2-methacryloyloxyethyl phosphorylcholine (MPC)-nanocapsules to deliver immunoglobulins (IgG), which can increase the delivery efficiency and specific target of IgG while reducing the effective therapeutic dose of the drug. RESULTS: Our results demonstrated that MPC-capsuled immunoglobulins (MPC-n (IgG)) significantly alleviated cognitive impairment, hippocampal atrophy, p-Tau deposition, and myelin injury in rmTBI mice compared with free IgG. Furthermore, MPC-n (IgG) can also effectively inhibit the activation of microglia and the release of inflammatory factors. CONCLUSIONS: In the present study, we put forward an efficient strategy for the treatment of rmTBI-related cognitive impairment and provide evidence for the administration of low-dose IgG.
Subject(s)
Brain Concussion , Cognitive Dysfunction , Neurodegenerative Diseases , Mice , Animals , Brain Concussion/complications , Brain Concussion/drug therapy , Brain Concussion/psychology , Disease Models, Animal , Cognitive Dysfunction/drug therapy , Immunoglobulin G , BrainABSTRACT
Transcription factors bind promoter or regulatory sequences of a gene to regulate its rate of transcription. However, they are also detected in anucleated platelets. The transcription factors RUNX1, GATA1, STAT3, NFκB, and PPAR have been widely reported to play key roles in the pathophysiology of platelet hyper-reactivity, thrombosis, and atherosclerosis. These non-transcriptional activities are independent of gene transcription or protein synthesis but their underlying mechanisms of action remain poorly defined. Genetic and acquired defects in these transcription factors are associated with the production of platelet microvesicles that are known to initiate and propagate coagulation and to promote thrombosis. In this review, we summarize recent developments in the study of transcription factors in platelet generation, reactivity, and production of microvesicles, with a focus on non-transcriptional activities of selected transcription factors.
Subject(s)
Megakaryocytes , Thrombosis , Humans , Megakaryocytes/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Blood Platelets/metabolism , Platelet Count , Thrombosis/metabolismABSTRACT
Traumatic brain injury (TBI)-induced neuroinflammation is closely associated with poor outcomes and high mortality in affected patients, with unmet needs for effective clinical interventions. A series of causal and disseminating factors have been identified to cause TBI-induced neuroinflammation. Among these are cellular microvesicles released from injured cerebral cells, endothelial cells, and platelets. In previous studies, we have put forward that cellular microvesicles can be released from injured brains that induce consumptive coagulopathy. Extracellular mitochondria accounted for 55.2% of these microvesicles and induced a redox-dependent platelet procoagulant activity that contributes to traumatic brain injury-induced coagulopathy and inflammation. These lead to the hypothesis that metabolically active extracellular mitochondria contribute to the neuroinflammation in traumatic brain injury, independent of their procoagulant activity. Here, we found that these extracellular mitochondria induced polarization of microglial M1-type pro-inflammatory phenotype, aggravating neuroinflammation, and mediated cerebral edema in a ROS-dependent manner. In addition, the effect of ROS can be alleviated by ROS inhibitor N-ethylmaleimide (NEM) in vitro experiments. These results revealed a novel pro-inflammatory activity of extracellular mitochondria that may contribute to traumatic brain injury-associated neuroinflammation.
Subject(s)
Brain Injuries, Traumatic , Microglia , Animals , Mice , Neuroinflammatory Diseases , Endothelial Cells , Reactive Oxygen Species/metabolism , Inflammation/metabolism , Brain Injuries, Traumatic/complications , Brain Injuries, Traumatic/metabolism , Mitochondria , Mice, Inbred C57BL , Disease Models, AnimalABSTRACT
In order to break the aging crude oil (WACO) emulsion of the offshore platform more effectively, a highly active isocyanate, polyaryl polymethylene isocyanate (PAPI), was selected to modify the pilot-scale tannic acid demulsifier. In the addition of PAPI, its molecular weight and viscosity dramatically increased, while its relative solubility, hydroxyl number, and cloud point exhibited an opposite direction, showing an increase in hydrophobicity. After adding the above modified demulsifier, a remarkably improved water removal of WACO emulsion accompanied by a notable reduction of the water content in the oil phase monitored by the Karl Fischer method was observed. Demulsification on the offshore platform demonstrated that the best water removal was achieved when the proportion of PAPI is 1.5 wt %. Its demulsification efficiency reached 95.7%, which was 25.6% higher than the 76.2% of unmodified demulsifier. In addition, a positive correlation between viscoelasticity of emulsion and demulsification performance was found by only adjusting the parameters of the rheometer. This method may be utilized to characterize the demulsification performance by any rotary rheometer. The pilot-scale demulsification experiment demonstrated that the water removal can reach 98.14 vol % and residual water content was only 0.55 vol %. These results further confirmed the excellent demulsification performance of the modified demulsifier toward the WACO emulsion in production.